Arthritis, Rheumatoid Clinical Trial
Official title:
A Randomized, Open-labelled Study to Compare the Efficacy and Safety of Meloxicam 15 mg IM Ampoules Once Daily and Meloxicam 15 mg Tablets Administered Orally Once Daily Over a Period of 7 Days in Patients With RA.
Verified date | July 2018 |
Source | Boehringer Ingelheim |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this trial was to assess the efficacy and safety of 15 mg meloxicam i.m. once daily compared with 15 mg meloxicam tablets once daily p.o. in patients with Rheumatoid arthritis over a time period of 7 days.
Status | Completed |
Enrollment | 150 |
Est. completion date | December 31, 2004 |
Est. primary completion date | December 1, 2004 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male or female aged 18 years or above - The patient has rheumatoid arthritis, as defined by the American Rheumatism Association. - Assessment of overall pain (by the patient), after a washout for NSAID of at least 2 days (3 days for oxicams), must exceed 40 mm on a 100 mm visual analogue scale (VAS) - Symptoms of RA requiring administration of NSAIDs - Outpatients - Willingness and ability to provide written informed consent. Exclusion Criteria: - Known or suspected hypersensitivity to the trial drugs or their excipients, analgesics, antipyretics or NSAIDs - Any clinical evidence of active peptic ulceration during the previous 6 months - Pregnancy or breastfeeding (precaution: attention should be drawn to reports that NSAIDs were reported to decrease the effectivity of intrauterine devices) - Asthma, nasal polyps, angioneurotic oedema or urticaria following the administration of aspirin or NSAIDs - Concomitant treatment with anti-coagulants (including heparin), lithium - Concomitant administration of other NSAIDs or analgesic agents (except paracetamol up to 4g/day) - Administration of any NSAID during the last 2 days (3 days for any oxicam) prior to the first administration of the trial drug - Concomitant treatment with methotrexate, sulfasalazine, D-penicillamine, chloroquine or any other disease modifying antirheumatic drug initiated or with an altered dose over the previous 3 months - Concomitant treatment with an oral corticosteroid initiated or with an altered dose over the previous month - Parenteral or intraarticular administration of corticosteroids in the previous month - Any i.m. injection during the previous 7 days - Synovectomy and/or surgical treatment for RA in the previous month or during the trial - Any physiotherapy which will be changed during the trial - Any contra-indication to i.m. injections - Clinical evidence of or known severe cardiac, hepatic, renal, metabolic, haematological disease, mental disturbance, ulcerative colitis - Any other rheumatological or non-rheumatological disease that could interfere with the evaluation of efficacy and safety - Serum creatinine 125 % of the upper limit of normal range ; aspartate amino-transferase (AST/SGOT) and/or alaline amino-transferase (ALT/SGPT) 200 % of the upper limit of normal range - Platelet count < 100,000/mm3 ; leucocytes count < 3,000/mm3 - Participation in another clinical trial during this study or during the previous month - Previous participation in this trial (i.e. having been allocated a randomized treatment number) - Patient unable to comply with the protocol |
Country | Name | City | State |
---|---|---|---|
China | Beijing Xuan Wu Hospital | Beijing | |
China | People's Hospital, Beijing University | Beijing | |
China | 1st Affiliated, Anhui Medical University | Hefei City, Anhui Province | |
China | Qilu Hospital, Shang Dong University | Nan City | |
China | Shanghai Changhai Hospital | Shanghai | |
China | Shanghai Guanghai Hospital | Shanghai | |
China | Shanghai Renji Hospital | Shanghai | |
China | Shanghai Zhongshan Hospital | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Boehringer Ingelheim |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patient's assessment of overall pain | 7 days | ||
Primary | Patient's global assessment of disease activity | 7 days | ||
Secondary | Investigator's Global Assessment of Disease Activity | 7 days | ||
Secondary | Tender/Painful Joint Count | 7 days | ||
Secondary | Swollen Joint Count | 7 days | ||
Secondary | Duration of Morning Stiffness | 7 days | ||
Secondary | Patient's assessment of physical function | 7 days | ||
Secondary | Final Global Assessment of Efficacy by Patient | 7 days | ||
Secondary | Final Global Assessment of Efficacy by Investigator | 7 days | ||
Secondary | Withdrawals due to Inadequate Efficacy | 7 days | ||
Secondary | Change in Patient Status With Regard to Arthritic Condition as Assessed by the Patient | 7 days | ||
Secondary | Change in Patient Status With Regard to Arthritic Condition as Assessed by the Investigator | 7 days | ||
Secondary | Onset of Analgesic Action | 7 days | ||
Secondary | Time to Maximum Pain Relief After the First Trial Drug Administration | 7 days | ||
Secondary | Paracetamol Consumption | 7 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01682512 -
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT00539760 -
A Phase I Rheumatoid Arthritis Study in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03312465 -
Anatomical Shoulder Domelock System Study
|
||
Completed |
NCT01208181 -
A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)
|
Phase 3 | |
Completed |
NCT03254810 -
Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT01711814 -
A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study
|
Phase 2 | |
Completed |
NCT03315494 -
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers
|
Phase 1 | |
Withdrawn |
NCT03241446 -
Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)
|
Phase 1 | |
Completed |
NCT02553018 -
Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe
|
Phase 3 | |
Completed |
NCT02748785 -
MTX Discontinuation and Vaccine Response
|
Phase 4 | |
Active, not recruiting |
NCT02260778 -
Treat-to-target in RA: Collaboration To Improve adOption and adhereNce
|
N/A | |
Completed |
NCT02569736 -
Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
|
||
Completed |
NCT01750931 -
This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.
|
Phase 2 | |
Withdrawn |
NCT01204138 -
Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA
|
Phase 2 | |
Not yet recruiting |
NCT01154647 -
Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes
|
N/A | |
Completed |
NCT00913458 -
Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis
|
Phase 4 | |
Completed |
NCT00975130 -
Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)
|
Phase 3 | |
Completed |
NCT00973479 -
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy
|
Phase 3 | |
Completed |
NCT00550446 -
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
|
Phase 2 | |
Completed |
NCT00660647 -
Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)
|
Phase 3 |